neuropilin-1(nrp1)

EG01377 2HCl is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1) with a Kd value of 1.32 μM and an IC50 value of 609 nM for both EG01377 2HCl against NRP1-a1 and NRP1-b1.EG01377 exhibits anti-angiogenic, antimigratory and antitumor activities.

EG00229 is a neuropilin 1 (NRP1) receptor antagonist that selectively inhibits the binding of VEGF-A to the NRP1 b1 domain with an IC50 value of 3 μM. It does not affect the binding of VEGF-A to other receptors, such as VEGFR-1 and VEGFR-2.

EG01377 has antiangiogenic, antimigratory, and antitumor effects.EG01377 is a neuropilin-1 (NRP1) antagonist, with a Kd of 1.32 μM for NRP1-b1, and IC50s of both 609 nM for NRP1-a1 and NRP1-b1, but shows no effect on NRP2.

EG01449 is a quinoline-based neuropilin-1 (NRP1) antagonist with a Kd of 0.6 µM. It competitively inhibits the binding of VEGFA to NRP1 with an IC50 of 362 nM, preventing VEGFA-induced pain by inhibiting NRP1-dependent signaling and reducing sodium currents in sensory neurons. EG01449 can cross the blood-brain barrier, allowing for targeted actions within the central nervous system, and is utilized in pain research.

EG01449 Free acid is a quinoline-based antagonist of neuropilin-1 (NRP1), exhibiting a Kd of 0.6 µM. It competitively inhibits the binding of VEGFA to NRP1, with an IC50 of 362 nM. By inhibiting NRP1-dependent signaling and reducing sodium currents in sensory neurons, EG01449 Free acid prevents VEGFA-induced pain. Additionally, it is capable of crossing the blood-brain barrier, allowing for targeted effects within the central nervous system. EG01449 Free acid is applicable for pain research.

EG01377 dihydrochloride is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1) , with a K d of 1.32 μM, and IC 50 s of 609 nM for both NRP1-a1 and NRP1-b1 . EG01377 dihydrochloride has antiangiogenic, antimigratory, and antitumor effects .

Vesencumab (MNRP-1685A) is an IG1 antibody targeting NRP-1 with anti-angiogenic and anti-tumor activity that reduces the number of globules formed by the SUM159 and Hs578T cell lines. Vesencumab inhibits EGFR and PDGFRα activation and can be used to study solid tumors.